WallStreetZenWallStreetZen

NASDAQ: NRXP
Nrx Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their NRXP stock forecasts and price targets.

Forecast return on equity

Is NRXP forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is NRXP forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

NRXP revenue forecast

What is NRXP's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$6.7M
Avg 2 year Forecast
$50.0M
Avg 3 year Forecast
$200.0M

NRXP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NRXP$3.52N/AN/A
ACHL$0.92$2.83+209.62%Hold
ICCC$4.80N/AN/A
PMN$2.00N/AN/A
IGC$0.60N/AN/A

Nrx Pharmaceuticals Stock Forecast FAQ

What is NRXP's revenue growth forecast for 2024-2027?

(NASDAQ: NRXP) Nrx Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.99%.

Nrx Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast NRXP's revenue for 2024 to be $71,694,080, with the lowest NRXP revenue forecast at $71,694,080, and the highest NRXP revenue forecast at $71,694,080. On average, 1 Wall Street analysts forecast NRXP's revenue for 2026 to be $535,030,450, with the lowest NRXP revenue forecast at $535,030,450, and the highest NRXP revenue forecast at $535,030,450.

In 2027, NRXP is forecast to generate $2,140,121,800 in revenue, with the lowest revenue forecast at $2,140,121,800 and the highest revenue forecast at $2,140,121,800.

If you're new to stock investing, here's how to buy Nrx Pharmaceuticals stock.

What is NRXP's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: NRXP) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is NRXP's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: NRXP) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.